Cassaday & Co Wealth Management
AIM icon

Cassaday & Co Wealth Management’s AIM ImmunoTech AIM Stock Holding History

Cassaday & Co Wealth Management’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1 Buy
+1
New – ﹤0.01% 1264

Other funds holding AIM

Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Continuum Advisory
Continuum Advisory Eagle, Idaho $1.23B AUM 21.4% 1-Year Est. Return
Community Bank
Community Bank Dewitt, New York $933M AUM 24.36% 1-Year Est. Return
Harbour Investments
Harbour Investments Madison, Wisconsin $6.75B AUM 16.25% 1-Year Est. Return
Creative Financial Designs
Creative Financial Designs Kokomo, Indiana $2.22B AUM 15.38% 1-Year Est. Return

Cassaday & Co Wealth Management's AIM Position: Q3 2026 in Review

Cassaday & Co Wealth Management opened a new position in AIM ImmunoTech (AIM) in Q3 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #1264 among its holdings.

15 funds tracked by Wall St. Rank hold AIM as of Q3 2026.

  • Cassaday & Co Wealth Management held 1 share of AIM ImmunoTech worth $1 as of Q3 2026.
  • AIM ImmunoTech was a new Cassaday & Co Wealth Management position in Q3 2026.
  • AIM ImmunoTech made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q3 2026, its #1264 holding.
  • 15 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q3 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q3 2026, filed 27 Oct 2026.